Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Equity Average (2018 - 2022)

Historic Equity Average for Iterum Therapeutics (ITRM) over the last 5 years, with Q3 2022 value amounting to $38.2 million.

  • Iterum Therapeutics' Equity Average fell 2329.11% to $38.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $38.2 million, marking a year-over-year decrease of 2329.11%. This contributed to the annual value of -$162500.0 for FY2021, which is 9957.68% up from last year.
  • As of Q3 2022, Iterum Therapeutics' Equity Average stood at $38.2 million, which was down 2329.11% from $46.3 million recorded in Q2 2022.
  • In the past 5 years, Iterum Therapeutics' Equity Average ranged from a high of $106.3 million in Q3 2018 and a low of -$53.2 million during Q4 2020
  • Moreover, its 5-year median value for Equity Average was $38.2 million (2022), whereas its average is $21.5 million.
  • Its Equity Average has fluctuated over the past 5 years, first plummeted by 58739.29% in 2020, then surged by 61921.54% in 2022.
  • Quarter analysis of 5 years shows Iterum Therapeutics' Equity Average stood at $82.9 million in 2018, then plummeted by 117.7% to -$14.7 million in 2019, then crashed by 262.93% to -$53.2 million in 2020, then soared by 196.45% to $51.3 million in 2021, then fell by 25.56% to $38.2 million in 2022.
  • Its last three reported values are $38.2 million in Q3 2022, $46.3 million for Q2 2022, and $49.4 million during Q1 2022.